drugset / Trial / NCT02908451
A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study is to define the safety profile and to determine the Maximal tolerated dose regimen and preliminary efficacy of AbGn-107 administered every 14 days (Q2W regimen) or 28 days (Q4W regimen) in patients with chemo-refractory locally advanced, recurrent or metastatic gastric, colorectal, pancreatic or biliary cancer.
Timeline
- Start
- 2017-04-24
- Primary completion
- 2021-02-28
- Completion
- 2021-02-28
Outcome
Outcome not reported
Stopped: “COVID-19 pandemic has caused a huge operational difficulty for this ongoing clinical trial, as many hospitals have set limitations on onsite staff, patient visits, study related procedures and onsite monitoring visits.”